Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Koichi Tomoshige (15304682) (author)
Beste egile batzuk:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Argitaratua:	2025
Gaiak:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
nork: Craig M. Goodwin (14955973)
Argitaratua: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
nork: Nicholas T. Younger (14956251)
Argitaratua: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
nork: Nicholas T. Younger (14956251)
Argitaratua: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
nork: Nicholas T. Younger (14956251)
Argitaratua: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
nork: Nicholas T. Younger (14956251)
Argitaratua: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
nork: Dhruv Chachad (14954640)
Argitaratua: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
nork: Dhruv Chachad (14954640)
Argitaratua: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
nork: Dhruv Chachad (14954640)
Argitaratua: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
nork: Dhruv Chachad (14954640)
Argitaratua: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
nork: Dhruv Chachad (14954640)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
nork: Man Xu (14963249)
Argitaratua: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
nork: Caleb N. Seavey (15056489)
Argitaratua: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
nork: Caleb N. Seavey (15056489)
Argitaratua: (2025)

Cannot write session to /tmp/vufind_sessions/sess_uqerg0ibjm2jt821k6qioc3gtc